✦ LIBER ✦

The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas

✍ Scribed by Ruth Sonnen; Wolf-Peter Schmidt; Hans Konrad Müller-Hermelink; Norbert Schmitz

Book ID: 108673166
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 153 KB
Volume: 129
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2005.05478.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The International Prognostic Index predi

The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma

✍ Moskowitz, C H; Nimer, S D; Glassman, J R; Portlock, C S; Yahalom, J; Straus, D 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 70 KB

Serum-soluble interleukin-2 receptor (sI

Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index

✍ Hideko Goto; Hisashi Tsurumi; Masao Takemura; Yoriko Ino-Shimomura; Senji Kasaha 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 244 KB

Plasma TNF-α and IL-10 Level-Based Progn

Plasma TNF-α and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index

✍ Ewa Lech-Maranda; Jacques Bienvenu; Florence Broussais-Guillaumot; Krzysztof War 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 236 KB

Reassessment of the prognostic factors o

Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population

✍ Shen Yang; Yao Yu; Li Jun-Min; Mi Jian-Qing; Chen Qiu-Sheng; Chen Yu; Zhao Wei-L 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 144 KB

CEOP treatment results and validity of t

CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma

✍ C. S. Chim; Y. L. Kwong; A. K. W. Lie; C. K. Lee; R. Liang 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 2 views

From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m 2 ) was used in place of doxorubicin (50 mg/m 2 ), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age wa

Application of the international prognos

Application of the international prognostic index in a study of chinese patients with non-hodgkin's lymphoma and a high incidence of primary extranodal lymphoma

✍ Tony S. Mok; Joyce Steinberg; Anthony T. Chan; Winnie M. Yeo; P. Hui; Thomas W. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 3 views

## Background: Chemotherapy containing anthracycline is the standard initial treatment for aggressive non-hodgkin's lymphoma (nhl), and the international prognostic index (ipi) is widely accepted as the standard tool for determining the prognosis of patients with this disease. however, the data on